Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results,
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Benzinga.com2d
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from ...
Barron's3d
Novo Nordisk A/S ADR
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Ozempic’s Price ‘Very Likely’ To Be Subject Of Medicare Negotiations, Report Says
President Joe Biden’s Inflation Reduction Act allows Medicare to negotiate costly drug prices with pharmaceutical companies.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
What the Options Market Tells Us About Novo Nordisk
Out of all of the special options we uncovered, 7 are puts, for a total amount of $295,009, and 5 are calls, for a total ...
Cantor Fitzgerald Remains a Buy on Novo Nordisk (NVO)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Novo Nordisk (NVO – Research Report) yesterday and set a price target of ...